Evolus Inc (NASDAQ: EOLS) kicked off on Monday, down -4.60% from the previous trading day, before settling in for the closing price of $11.53. Over the past 52 weeks, EOLS has traded in a range of $9.95-$17.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 55.81%. While this was happening, its average annual earnings per share was recorded 65.65%. With a float of $54.70 million, this company’s outstanding shares have now reached $63.25 million.
Let’s determine the extent of company efficiency that accounts for 273 employees. In terms of profitability, gross margin is 68.25%, operating margin of -13.69%, and the pretax margin is -22.2%.
Evolus Inc (EOLS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Evolus Inc is 13.62%, while institutional ownership is 79.75%. The most recent insider transaction that took place on Dec 23 ’24, was worth 24,438. In this transaction an insider of this company sold 2,252 shares at a rate of $10.85, taking the stock ownership to the 366,595 shares. Before that another transaction happened on Dec 23 ’24, when Company’s Chief Financial Officer sold 1,586 for $10.85, making the entire transaction worth $17,211. This insider now owns 146,916 shares in total.
Evolus Inc (EOLS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 65.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.50% during the next five years compared to 10.81% growth over the previous five years of trading.
Evolus Inc (NASDAQ: EOLS) Trading Performance Indicators
Take a look at Evolus Inc’s (EOLS) current performance indicators. Last quarter, stock had a quick ratio of 2.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Evolus Inc (EOLS)
Looking closely at Evolus Inc (NASDAQ: EOLS), its last 5-days average volume was 0.78 million, which is a drop from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 62.06%. Additionally, its Average True Range was 0.56.
During the past 100 days, Evolus Inc’s (EOLS) raw stochastic average was set at 5.54%, which indicates a significant decrease from 32.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.57% in the past 14 days, which was lower than the 51.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.01, while its 200-day Moving Average is $13.43. However, in the short run, Evolus Inc’s stock first resistance to watch stands at $11.43. Second resistance stands at $11.87. The third major resistance level sits at $12.12. If the price goes on to break the first support level at $10.74, it is likely to go to the next support level at $10.49. Should the price break the second support level, the third support level stands at $10.05.
Evolus Inc (NASDAQ: EOLS) Key Stats
The company with the Market Capitalisation of 696.54 million has total of 63,321K Shares Outstanding. Its annual sales at the moment are 202,090 K in contrast with the sum of -61,690 K annual income. Company’s last quarter sales were recorded 61,090 K and last quarter income was -19,170 K.
